| | | EntreMed's ENMD-2076 Demonstrates Significant Anti-Cancer Activity In Multiple Myeloma Preclinical Models |  | Advertisements: |
|  07/14/10 EntreMed, Inc. (Nasdaq: ENMDD), announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma (MM) cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana ... READ FULL SOURCE |
Back to: Aurora IN news
Other news07/13/10 EntreMed, Inc. , today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. ? Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University ... Hot themes this week:
|
| |
| | HOT towns and cities: Ossian, IN news • Floyds Knobs, IN news • Jasper, IN news • Lawrence, IN news • Ferdinand, IN news • Clinton, IN news • Lafayette, IN news • Dyer, IN news • Downtown Indianapolis, IN news • Newburgh, IN news • Geist, IN news • Brooklyn, IN news • Indianapolis East, IN news | |
|
(c) ProvinceCity.com - news and events from small towns, cities and megapolises.
All rights reserved. |
| |
Home Sitemap 0 news added |
|
|
